SCHEMBL990794

SCHEMBL990794

O=C(CCc1cc2ccccc2[nH]1)N[C@H]1CCC[C@@](O)(C#Cc2cccc(Cl)c2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.41
GRM5 P41594 1/20 0.40
FPR3 P25089 1/20 0.38
FPR2 P25090 1/20 0.38
SMYD3 Q9H7B4 2/20 0.36
THRB P10828 1/20 0.36
HPGD P15428 1/20 0.36
EPHX2 P34913 1/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
NPC1 O15118 1/20 0.35
PIN1 Q13526 1/20 0.35
GID4 Q8IVV7 1/20 0.35
SSTR3 P32745 1/20 0.35
HDAC1 Q13547 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
TNKS O95271 3/20 0.34
PARP1 P09874 2/20 0.34
PARP2 Q9UGN5 2/20 0.34
MTNR1A P48039 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990820 0.81 HPGD (0.41) GRM5THRBHPGDEPHX2BCHE
SCHEMBL990965 0.80 GRM5 (0.44) GRM5THRBHPGDEPHX2NPC1
SCHEMBL16390663 0.80 EPHX2 (0.53) GRM5THRBHPGDEPHX2
SCHEMBL990289 0.80 EPHX2 (0.53) GRM5THRBHPGDEPHX2
SCHEMBL990846 0.77 NPC1 (0.46) GRM5EPHX2NPC1
SCHEMBL4722043 0.76 PLAAT3 (0.44) GRM5THRBHPGDEPHX2NPC1
SCHEMBL992293 0.76 SMYD3 (0.46) GRM5SMYD3
SCHEMBL990340 0.75 L3MBTL1 (0.59) GRM5NPC1L3MBTL1
SCHEMBL991376 0.75 HPGD (0.55) GRM5HPGDNPC1L3MBTL1
SCHEMBL4656000 0.75 HPGD (0.55) GRM5HPGDNPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272509-A1 New Uses of metabotropic glutamate receptors Novartis AG (CH) 2011-01-12 EP disclosed
US-20100099682-A1 ACETYLENE DERIVATIVES NOVARTIS AG 2010-04-22 US disclosed
US-7696379-B2 Acetylene derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
US-20080214673-A1 Acetylene Derivatives NOVARTIS AG (CH) 2008-09-04 US disclosed
EP-1877365-A1 ACETYLENE DERIVATIVES Novartis AG (CH) 2008-01-16 EP disclosed
WO-2006114262-A1 ACETYLENE DERIVATIVES NOVARTIS AG (CH) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099682-A1 ACETYLENE DERIVATIVES NAT1, NAT10, F12 MDM2 3407/4885GRM5 3794/4885FPR3 719/4885
US-20080214673-A1 Acetylene Derivatives NAT1, NAT10, F12 MDM2 3407/4885GRM5 3794/4885FPR3 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.